Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

20:01
 
Share
 

Manage episode 465989778 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:

  • Early results with teclistamab combined with anti-CD38 therapy
  • Real-world data with teclistamab including its use after other BCMA-targeted therapies
  • Talquetamab as bridging therapy to BCMA-targeted CAR T-cell therapy
  • Evaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapy

Presenter:
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematologic Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Associate Chair for Research, Department of Medicine
Mayo Clinic
Rochester, Minnesota

Link to full program:
https://bit.ly/40bjFCZ

  continue reading

194 episodes

Artwork
iconShare
 
Manage episode 465989778 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:

  • Early results with teclistamab combined with anti-CD38 therapy
  • Real-world data with teclistamab including its use after other BCMA-targeted therapies
  • Talquetamab as bridging therapy to BCMA-targeted CAR T-cell therapy
  • Evaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapy

Presenter:
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematologic Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Associate Chair for Research, Department of Medicine
Mayo Clinic
Rochester, Minnesota

Link to full program:
https://bit.ly/40bjFCZ

  continue reading

194 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play